40例原发性胃肠道弥漫大B细胞淋巴瘤临床诊疗分析  

Analysis of diagnosis and treatment of 40 patients with primary gastrointestinal diffuse large B-cell lymphoma

作　　者：王飞[1] 翟敏[1] 武亚运 张海涛[1] 赵鑫[1] 

机构地区：[1]苏州大学附属第一医院普外科,江苏苏州215006

出　　处：《中国医师进修杂志》2017年第3期250-254,共5页Chinese Journal of Postgraduates of Medicine

基　　金：国家自然科学基金（81302146）;江苏省自然科学基金（BK20161225）;江苏省高校自然科学基金（13KJB320018）;中国博士后基金（2016M591913）;江苏省苏州市科技计划（SYS201539）

摘　　要：目的 探讨原发性胃肠道弥漫大B细胞淋巴瘤（PGI-DLBCL）的临床特点、诊治方法及预后.方法 对经手术治疗的40例PGI-DLBCL患者的临床资料进行回顾性分析.结果40例PGI-DLBCL患者中,首发症状以腹痛[15例（37.5%）]、腹部包块[6例（15.0%）]、腹部不适[5例（12.5%）]、腹胀[5例（12.5%）]、呕血黑便[5例（12.5%）]为主.误诊为胃癌15例,肠癌5例,消化道溃疡4例,总误诊率为60.0%（24/40）.1、2、3年生存率分别为62.3%、57.5%、52.6%.单因素分析结果显示,临床分期、国际预后指数（IPI）和治疗方法与生存率有关（P〈0.01）,性别、年龄和原发部位与生存率无关（P〉0.05）.临床分期Ⅰ~Ⅱ期患者3年生存率明显高于Ⅲ~Ⅳ期患者（68.0%比13.3%）,IPI 0~2分患者3年生存率明显高于3~5分患者（66.7%比7.6%）,手术联合术后化疗患者3年生存率明显高于单纯手术患者（75.0%比20.0%）,差异有统计学意义（P〈0.01）.结论 PGI-DLBCL患者临床特征不典型,极易误诊.IPI、临床分期、术后是否化疗是预后的影响因素.Objective To study the clinical characteristics, treatment methods and prognosis of primary gastrointestinal diffuse large B-cell lymphoma （PGI-DLBCL）. Methods The clinical data of 40 patients with PGI- DLBCL were retrospectively analyzed. All the cases had received surgery treatment. Results In 40 patients with PGI-DLBCL, the major clinical presentation included abdominal pain in 15 cases （37.5%）, abdominal mass in 6 cases （15.0%）, abdominal discomfort in 5 cases （12.5%）, abdominal distension in 5 cases （12.5%）, and hematemesis in 5 cases （12.5%）. Fifteen cases were misdiagnosed as gastric cancer, 5 cases as colon cancer, and 4 cases as digestive tract ulcer. The misdiagnosis rate was 60.0% （24/40）. The survival rates of 1- , 2- and 3- year were 62.3%, 57.5% and 52.6%. The univariate analyses result showed that the clinical stage, international prognosis index （IPI） and treatment method were associated with survival rate （P〈0.01）, but the gender, age and disease distribution were not associated with survival rate （P 〉 0.05）. The 3-year survival rate of clinical stage Ⅰ - Ⅱ was significantly higher than clinical stageⅢ-Ⅳ（68.0%vs. 13.3%）, the 3-year survival rate of IPI 0-2 scores was significantly higher than 3 - 5 scores （66.7% vs. 7.6%）, and the 3- year survival rate of surgery combined with postoperative chemotherapy was significantly higher than simple surgery （75.0%vs. 20.0%）, there were statistical differences （P〈0.01）. Conclusions The patients with PGI- DLBCL have no obvious clinical manifestions and a higher misdiagnosed rate. Modified IPI, clinical stage and surgery combined with postoperative chemotherapy are the influencing factors of prognosis.

关 键 词：淋巴瘤 大BV细胞 弥漫性 胃肠道 预后 回顾性研究 

分 类 号：R735[医药卫生—肿瘤]